MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin

Table 3 MOG-IgG, MOG-IgG1, MOG-IgM, and MOG-IgA results from 21 samples

No	MOG-IgG1	MOG-IgG	MOG-IgM	MOG-IgA	Disease status
1	POS	POS	NEG	NEG	Relapse
2	POS	POS	NEG	NEG	Relapse
3A	POS	POS	NEG	NEG	Relapse
3B	POS	POS	NEG	NEG	Remission
4	POS	POS	NEG	NEG	Remission
5	POS	POS	NEG	NEG	Remission
6	POS	POS	NEG	NEG	Remission
7	POS	POS	NEG	NEG	Remission
8	POS	POS	NEG	NEG	Relapse
9A	POS	POS	NEG	NEG	Relapse
9B	n.d.	POS	NEG	NEG	Remission
10A	POS	POS	NEG	NEG	Relapse
10B	n.d.	POS	NEG	NEG	Remission
11	n.d.	POS	NEG	NEG	Relapse
12	n.d.	POS	NEG	NEG	Remission
13	n.d.	POS	NEG	NEG	Remission
14A	n.d.	POS 1:1000	POS 1:20	NEG	Relapse
14B	n.d.	POS 1:100	POS 1:10	NEG	Remission
15A	n.d.	POS	NEG	NEG	Remission
15B	n.d.	POS	NEG	NEG	Remission
16	POS	POS	n.d.	n.d.	Relapse
17	POS	POS	n.d.	n.d.	Relapse
18	POS	POS	n.d.	n.d.	Relapse

MOG-IgG was determined using a commercial fixed CBA (cut-off 1:10). MOG-IgG1 was also present in 3/3 CSF samples from MOG-IgG1-seropositive patients (not shown). POS positive, NEG negative, n.d not done

ISSN: 1742-2094